Skip to main content
. 2016 Jul 12;7(32):51626–51639. doi: 10.18632/oncotarget.10539

Figure 4. Anti-tumor efficacy of dasatinib (a SRC inhibitor) and PKI-587 (a PI3K/mTOR inhibitor) in 138T muscle-invasive bladder cancer harboring mutual EGFR amplification and PTEN deletion.

Figure 4

(A) Dose-response relationship curves of dasatinib and PKI-587 in 138T patient derived cell (PDC) tumors. Error bar represent the means ± SEM (triplicate). (B) Representative images of immunohistochemical staining of 138T PDC tumor tissue with antibodies against p-SRC (Tyr416) and p-AKT (Ser473). Scale bars, 100 μm. (C) 5′-ethynyl-2′-deoxyuridine (EdU) and cleaved caspase-3 analysis of 138T PDC tumors treated with dasatinib (Dose = 0, 0.5, or 1 μM) or PKI-587 (Dose = 0, 0.5, or 1 μM). Representative graphical analysis of EdU (+) and cleaved caspase-3 (+) cells following dasatinib or PKI-587 treatment; error bars represent the means ± SD. Representative images of EdU and cleaved caspase-3 staining following treatment (right).